Lumida
/SBC
⌘K
SBC Medical Group Holdings Inc

SBC Medical Group Holdings Inc

SBC
$4.46USD↑+1.36%+0.06 today

MARKET CAP

458.7M

P/E (TTM)

9.2x

FWD P/E

9.8x

DAY RANGE

$4 – $5

52W RANGE

$3
$5

AI Summary

Stalk
TrimMedium

SBC remains in a Stage 4 decline with persistent lower highs and lower lows and price trading below all major EMAs. The medium-term bias is bearish, as the active Post-Capitulation pattern signals only exhaustion without structural repair. Extreme oversold conditions counsel caution, so execution will focus on trimming into rallies toward the 9/20 EMA resistance zone.

  • ↑Underlying revenue grew 111% YoY (ex-$8.7M fee impact) reflecting strong recovery
  • ↑EBITDA +117% (ex-fee adjustments) underscoring improving margin trajectory
  • ↓Total revenue -9% YoY to $43M after April fee structure changes
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

SBC Medical Group Holdings Incorporated (NASDAQ: SBC) is a leading player in Japan's aesthetic medical sector, focused on providing a comprehensive array of clinic services targeting diverse customer demographics. The company employs a multi-brand strategy, which facilitates its approach towards niche market segments while enhancing customer personalization and trust. With growing patient demand for non-surgical aesthetic treatments and strategic investments in technology and partnerships, SBC is positioned at the forefront of the evolving healthcare landscape.

Bull says

  • ↑Underlying revenue grew 111% YoY (ex-$8.7M fee impact) reflecting strong recovery
  • ↑EBITDA +117% (ex-fee adjustments) underscoring improving margin trajectory
  • ↑Maintains solid cash reserves for pursuing high-potential M&A deals
  • ↑72% repeat customer ratio signals strong retention and service appeal
  • ↑Multi-brand strategy expands reach across demographics, balancing pricing and service
  • ↑Japan aesthetic market sees 10% annual growth, tripling client potential

Bear says

  • ↓Total revenue -9% YoY to $43M after April fee structure changes
  • ↓Leverage risk elevated, indicating high debt burden and refinancing concerns
  • ↓Profitability weak; average customer spending down and negative profit scores
  • ↓Liquidity low, limited share trading hampers buybacks and investor access
  • ↓Intense competition in Japan’s aesthetic market pressures pricing and growth
  • ↓High volatility and negligible dividend yield deter risk-averse investors

Earnings Call · Q2 2025 · Mgmt. Guidance

Updated 08-18-2026bullish

Transcript signals

Bull points

  • We are also strengthening support for franchise clinics in response to market changes. Specifically, we advise on shifting to higher margin models and support their implementation. Two clinics completed such transition in the first half showing clear financial improvements. Three more clinics are currently undergoing similar transformations, contributing to stable, medium to long-term operations.
  • Currently, Yen is weakening, so there are many inbound tourists coming to Japan. So we are focusing on and enhancing our medical tourism business. We are particularly focused on the Chinese tourist. Enhancing log out through a popular platform where increasing interpreters and hosting events in Shanghai. These initiatives have yielded strong results.
  • We are ranked on the seventh right now in Japan. I think that we can increase the number of clinics from seven to 100 moving forward. Fertility in the business is another important business area. and our hair loss services include medication transplantation and laser therapies. This comprehensive approach sets SPC apart as most AGA clinics focus only on medication. We are offering a comprehensive treatment that is our strength in Japan. We are from on the second place in terms of the market share in Japan. So within this year or next year, we now try to be a number one. Our target within 10 years is in an auto, fertility, and AJA. We want to be the number one market leader in those areas in Japan moving forward.

Bear points

  • We recognize that liquidity in our shares remains limited, making trading difficult for many institutional investors. To address this, we are working to improve the supply-demand balance and are considering new share issuance and purchase sales by the founder. These steps aim to improve accessibility for a broader investor base.
  • We recognize that liquidity in our shares remains limited, making trading difficult for many institutional investors. To address this, we are working to improve the supply-demand balance and are considering new share issuance and purchase sales by the founder. These steps aim to improve accessibility for a broader investor base.
  • We recognize that liquidity in our shares remains limited, making trading difficult for many institutional investors. To address this, we are working to improve the supply-demand balance and are considering new share issuance and purchase sales by the founder. These steps aim to improve accessibility for a broader investor base.
Read full transcript analysis ›